PR Newswire BiotechOriginal article
Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
RegulatoryVectorMist™Positive
AI Analysis
Summary
Vector Science & Therapeutics reports first quarterly results as a public company with peptide manufacturing revenue expected in August 2026 and VectorMist™ 510(k) submission advancing toward FDA filing.
Financial Highlights
Guidance
Peptide manufacturing vertical on track to begin generating revenue in August 2026
Outcome Details
510(k) submission advancing toward FDA filing
Importance:5/10
Sentiment:
0.50
EarningsRegulatoryIPOFDA FilingRevenue Guidance
Related Companies
Read the original article
Published by PR Newswire Biotech on July 24, 2026 10:37 PM